Pancreatic ductal adenocarcinoma (PDAC) is one of the most deadly forms of cancer, primarily due to the resistance of PDAC tumors to current therapeutic strategies. Several lines of evidence suggest that ineffective delivery of chemotherapy agents to tumor cells in the pancreas contributes to PDAC-associated treatment resistance. In this episode, Eugene Koay and Jason Fleming discuss the results of their clinical study that links pancreatic transport properties collected from PDAC patient CT scans with survival and response to the chemotherapy agent gemcitabine.
Eugene J. Koay, Mark J. Truty, Vittorio Cristini, Ryan M. Thomas, Rong Chen, Deyali Chatterjee, Ya’an Kang, Priya R. Bhosale, Eric P. Tamm, Christopher H. Crane, Milind Javle, Matthew H. Katz, Vijaya N. Gottumukkala, Marc A. Rozner, Haifa Shen, Jeffery E. Lee, Huamin Wang, Yuling Chen, William Plunkett, James L. Abbruzzese, Robert A. Wolff, Gauri R. Varadhachary, Mauro Ferrari, Jason B. Fleming